News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
H. Lundbeck A/S Braces For 2012-14 Profit Slide
November 3, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
COPENHAGEN, Nov 3 (Reuters) - Drugmaker Lundbeck (LUN.CO) on Wednesday spelled out for the first time the likely cost of generic competition to its key drug, warning profit could slide by a third in 2012-2014.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Manufacturing
Roche makes $300M China Production Promise After Multibillion US Investment
May 12, 2025
·
2 min read
·
Tristan Manalac
Legal
BMS, Sanofi Settle Plavix Suit With Hawaii for $700M
May 12, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Insitro Cuts 22% of Workforce, Extending Runway Into 2027
May 9, 2025
·
2 min read
·
Angela Gabriel
Layoffs
Sanofi Cuts Off Antibody Partner, Forcing 80% Headcount Reduction at IGM
May 9, 2025
·
2 min read
·
Tristan Manalac